Our focus is developing highly-differentiated therapies against validated targets in oncology.
Our lead program is a best-in-class potential TROP2-targeted antibody drug conjugate (ADC), PBI-410.
Trophoblast cell surface antigen 2 (TROP-2)
TROP-2 is a cell surface protein that is overexpressed in a wide variety of tumors. TROP-2 is a validated target in oncology, with earlier generation TROP-2 ADCs showing clinical activity in patients with TROP2-expressing tumors.
A Highly Differentiated, Best-In-Class Profile
In in vivo preclinical TROP-2 expressing tumor models, PBI-410 has shown improved antitumor activity versus other TROP-2 ADCs. It also has demonstrated more potent in vitro cytotoxicity, superior bystander effect, and greater immunogenic cell death with the novel TopoIx payload as compared to other Topoisomerase 1-based payloads.
PBI-410 has also shown compelling in vivo synergistic growth inhibition in combination with anti-PD-1 therapy in a mouse syngeneic MC38 colon cancer model, superior to the activity observed with other TROP-2 ADC plus anti-PD1 combinations.
Preclinical safety findings of PBI-410 in non-human primates indicate a differentiated profile and potential for a wider therapeutic window vs other TROP-2 ADCs in development.